PubMed:23704121 / 1288-1571 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PubMed/sourceid/23704121","sourcedb":"PubMed","sourceid":"23704121","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/23704121","text":"Given the current cost and NAP1/BI/027 accounting for approximately 50% of isolates, using fidaxomicin as a first-line treatment for CDI is not cost-effective. However, typing and treatment with fidaxomicin based on strain may be more promising depending on the costs of fidaxomicin.","tracks":[{"project":"bionlp-st-bb3-2016-training","denotations":[{"id":"T5","span":{"begin":0,"end":283},"obj":"Paragraph"}],"attributes":[{"subj":"T5","pred":"source","obj":"bionlp-st-bb3-2016-training"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"bionlp-st-bb3-2016-training","color":"#aa93ec","default":true}]}]}}